SCHEMBL22651961

SCHEMBL22651961

CC(C)n1cnc2c(N(C)c3ccccc3)nc(NC(CO)CO)nc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.70
▸ CDK5 Q00535 13/20 0.56
▸ CDK1 P06493 11/20 0.56
▸ CDK2 P24941 10/20 0.56
▸ CCNE1 P24864 6/20 0.56
▸ DYRK1A Q13627 5/20 0.56
▸ CCNA2 P20248 5/20 0.56
▸ CCNA1 P78396 5/20 0.56
▸ CDK5R1 Q15078 5/20 0.56
▸ CDK7 P50613 4/20 0.56
▸ CDK9 P50750 4/20 0.56
▸ CCNK O75909 3/20 0.56
▸ CDK12 Q9NYV4 3/20 0.56
▸ MAPK1 P28482 3/20 0.56
▸ CCNB1 P14635 3/20 0.56
▸ CCNE2 O96020 3/20 0.56
▸ CSNK1D P48730 2/20 0.56
▸ CLK2 P49760 2/20 0.56
▸ CSNK1G2 P78368 2/20 0.56
▸ CLK4 Q9HAZ1 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30356263 0.95 NPSR1 (0.67) NPSR1CDK5CDK1CDK2CCNE1
SCHEMBL19112178 0.95 NPSR1 (0.67) NPSR1CDK5CDK1CDK2CCNE1
SCHEMBL19112192 0.95 NPSR1 (0.67) NPSR1CDK5CDK1CDK2CCNE1
SCHEMBL15387124 0.95 NPSR1 (0.67) NPSR1CDK5CDK1CDK2CCNE1
Hydrochloric Acid SCHEMBL23927317 0.94 NPSR1 (0.66) NPSR1CDK5CDK1CDK2CCNE1
Hydrochloric Acid SCHEMBL30268945 0.94 NPSR1 (0.66) NPSR1CDK5CDK1CDK2CCNE1
Hydrochloric Acid SCHEMBL23927315 0.94 NPSR1 (0.66) NPSR1CDK5CDK1CDK2CCNE1
SCHEMBL17628572 0.89 CDK2 (0.66) NPSR1CDK5CDK1CDK2CCNE1
SCHEMBL23993161 0.86 CDK1 (0.65) NPSR1CDK5CDK1CDK2CCNE1
SCHEMBL19112102 0.85 CDK1 (0.63) NPSR1CDK5CDK1CDK2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181592-A1 PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2023-06-15 — — US disclosed
US-11472807-B2 Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) 2022-10-18 — — US disclosed
EP-3901154-A1 PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2021-10-27 — — EP disclosed
US-20200354364-A1 PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) 2020-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181592-A1 PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES ADORA1, OXGR1, ADORA2A NPSR1 266/4885CDK5 1097/4885CDK1 981/4885
US-11472807-B2 Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders TPMT, ADORA2A, PNP NPSR1 558/4885CDK5 1217/4885CDK1 2687/4885
US-20200354364-A1 PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS TPMT, ADORA2A, PNP NPSR1 558/4885CDK5 1217/4885CDK1 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback